Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Adult
Aged
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Carcinoma, Renal Cell
/ drug therapy
Everolimus
/ administration & dosage
Female
Histone Deacetylase Inhibitors
/ administration & dosage
Humans
Kaplan-Meier Estimate
Kidney Neoplasms
/ drug therapy
Male
MicroRNAs
Middle Aged
Panobinostat
/ administration & dosage
Progression-Free Survival
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Kidney
MicroRNA
Neoplasm
Targeted therapy
miR-605
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
28
08
2019
accepted:
09
10
2019
pubmed:
28
10
2019
medline:
10
9
2021
entrez:
27
10
2019
Statut:
ppublish
Résumé
Background Preclinical studies suggested synergistic anti-tumor activity when pairing mTOR inhibitors with histone deacetylase (HDAC) inhibitors. We completed a phase I, dose-finding trial for the mTOR inhibitor everolimus combined with the HDAC inhibitor panobinostat in advanced clear cell renal cell carcinoma (ccRCC) patients. We additionally investigated expression of microRNA 605 (miR-605) in serum samples obtained from trial participants. Patients and Methods Twenty-one patients completed our single institution, non-randomized, open-label, dose-escalation phase 1 trial. miR-605 levels were measured at cycle 1/day 1 (C1D1) and C2D1. Delta Ct method was utilized to evaluate miR-605 expression using U6B as an endogenous control. Results There were 3 dosing-limiting toxicities (DLTs): grade 4 thrombocytopenia (n = 1), grade 3 thrombocytopenia (n = 1), and grade 3 neutropenia (n = 1). Everolimus 5 mg PO daily and panobinostat 10 mg PO 3 times weekly (weeks 1 and 2) given in 21-day cycles was the recommended phase II dosing based on their maximum tolerated dose. The 6-month progression-free survival was 31% with a median of 4.1 months (95% confidence internal; 2.0-7.1). There was higher baseline expression of miR-605 in patients with progressive disease (PD) vs those with stable disease (SD) (p = 0.0112). PD patients' miR-605 levels decreased after the 1st cycle (p = 0.0245), whereas SD patients' miR-605 levels increased (p = 0.0179). Conclusion A safe and tolerable dosing regimen was established for combination everolimus/panobinostat therapy with myelosuppression as the major DLT. This therapeutic pairing did not appear to improve clinical outcomes in our group of patients with advanced ccRCC. There was differential expression of miR-605 that correlated with treatment response. Clinical trial information: NCT01582009.
Identifiants
pubmed: 31654285
doi: 10.1007/s10637-019-00864-7
pii: 10.1007/s10637-019-00864-7
pmc: PMC7182475
mid: NIHMS1541537
doi:
Substances chimiques
Antineoplastic Agents
0
Histone Deacetylase Inhibitors
0
MIRN605 microRNA, human
0
MicroRNAs
0
Panobinostat
9647FM7Y3Z
Everolimus
9HW64Q8G6G
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Banques de données
ClinicalTrials.gov
['NCT01582009']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1108-1116Subventions
Organisme : NCI NIH HHS
ID : R01 CA135321
Pays : United States
Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Biomed Biotechnol. 2011;2011:197946
pubmed: 21151670
Mutagenesis. 2019 May 29;34(2):127-133
pubmed: 30852614
Therapy. 2011 Jul;8(4):359-367
pubmed: 21894244
J Clin Oncol. 2008 Apr 1;26(10):1603-10
pubmed: 18332469
Mol Biol Cell. 2017 Dec 15;28(26):3756-3772
pubmed: 29074567
Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52
pubmed: 21763970
J Biol Chem. 2006 May 12;281(19):13612-9
pubmed: 16543236
Genes (Basel). 2018 Aug 22;9(9):
pubmed: 30135399
BJU Int. 2008 Aug;102(3):358-63
pubmed: 18394010
J Clin Oncol. 2008 Nov 20;26(33):5422-8
pubmed: 18936475
Cancer Invest. 2011 Aug;29(7):451-5
pubmed: 21696296
Chin J Cancer. 2016 Aug 11;35(1):77
pubmed: 27515039
Life Sci. 2017 Dec 1;190:7-14
pubmed: 28943214
J Urol. 2008 Sep;180(3):1131-6
pubmed: 18639283
Clin Lab. 2018 Oct 31;64(11):
pubmed: 30549993
Cancer Genet. 2015 Jan-Feb;208(1-2):47-51
pubmed: 25683625
Clin Cancer Res. 2005 May 1;11(9):3535-42
pubmed: 15867257
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Mol Oncol. 2012 Dec;6(6):590-610
pubmed: 23102669
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Invest New Drugs. 2015 Oct;33(5):1040-7
pubmed: 26091915
Clin Cancer Res. 2017 Sep 1;23(17):5187-5201
pubmed: 28698201
Ther Adv Hematol. 2014 Dec;5(6):197-210
pubmed: 25469210
Oncotarget. 2017 Aug 7;8(48):83913-83924
pubmed: 29137392
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Clin Cancer Res. 2017 Dec 1;23(23):7199-7208
pubmed: 28939740
Clin Cancer Res. 2008 Jun 1;14(11):3589-97
pubmed: 18519793
Ann Clin Lab Sci. 2006 Summer;36(3):283-93
pubmed: 16951269
J Clin Oncol. 2017 Apr 10;35(11):1231-1239
pubmed: 28221861
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Clin Oncol. 2014 Sep 1;32(25):2765-72
pubmed: 25049330
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
EMBO J. 2011 Feb 2;30(3):524-32
pubmed: 21217645
Br J Cancer. 2017 Mar 28;116(7):874-883
pubmed: 28222071
FEBS Lett. 2014 Sep 17;588(18):3491-500
pubmed: 25131931
Microrna. 2019;8(2):94-100
pubmed: 30514199
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Lancet Oncol. 2014 Oct;15(11):1195-206
pubmed: 25242045
J Cancer Biol Res. 2016;4(4):
pubmed: 28191499
Science. 2005 Feb 18;307(5712):1098-101
pubmed: 15718470
BMC Cancer. 2008 Dec 19;8:381
pubmed: 19099586